<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="493">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04408040</url>
  </required_header>
  <id_info>
    <org_study_id>NSH 1281</org_study_id>
    <nct_id>NCT04408040</nct_id>
  </id_info>
  <brief_title>Use of Convalescent Plasma for COVID-19</brief_title>
  <official_title>Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northside Hospital, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northside Hospital, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The plan is to transfuse COVID-19 infected patients with convalescent plasma and observe
      whether this will result in a significant improvement in clinical outcome in comparison to
      historical experience.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arms 1 &amp; 2: number of critical and severe COVID-19 infected patients who are transfused with convalescent plasma result in lower death rates than the reported fatality rate</measure>
    <time_frame>30 days after initial treatment</time_frame>
    <description>To estimate infection-related mortality rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arms 1 &amp; 2: number of critical and severe COVID-19 infected patients who survive the infection</measure>
    <time_frame>30 days after initial treatment</time_frame>
    <description>To estimate overall survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 3: number of high risk COVID-19 infected patients who are transfused with convalescent plasma result in lower incidence of progression to severe or critical disease than the reported case rate</measure>
    <time_frame>30 days after initial treatment</time_frame>
    <description>To estimate progression incidence rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 4: number of health care providers who are at risk to exposure to COVID-19 who are transfused with convalescent plasma result in lower incidence of developing COVID-19 infection than the reported case rate</measure>
    <time_frame>30 days after initial treatment</time_frame>
    <description>To estimate the rate of infection among healthy persons exposed to COVID-19</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Critical Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Care Providers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>200-425mL convalescent plasma donated by patients previously positive for COVID-19</description>
    <arm_group_label>Critical Patients</arm_group_label>
    <arm_group_label>Health Care Providers</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Severe Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented COVID-19 infection by nasal pharyngeal sampling

          -  COVID-19 disease falling into one of the following groups:

          -  Critical disease: respiratory failure requiring mechanical ventilation, pressor
             support, or multiple organ dysfunction/failure

          -  Severe disease: tachypnea &gt;/=30 per min, O2 sats &lt;/=93% at rest, PaO2/FiO2 index
             &lt;/=300mmHg

          -  High Risk: upper respiratory symptoms but no radiographic evidence of disease,
             immunocompromised, insulin-dependent diabetes, poorly controlled HIV disease, moderate
             to severe asthma history, severe COPD, morbid obesity (BMI &gt;/=40, age &gt;/=65 years

          -  Health Care Providers: health care providers at risk to exposure to COVID-19 infection
             or those with mild to non-severe disease

        Exclusion Criteria:

          -  History of IgA deficiency

          -  History of anaphylatic reaction to blood product transfusion including
             hypersensitivity to immunoglobulin therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent Holland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northside Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacey Brown</last_name>
    <phone>404-780-7965</phone>
    <email>stacey.brown@northside.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Brown, BA</last_name>
      <phone>404-780-7965</phone>
      <email>stacey.brown@northside.com</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Guzowski, MBA, MHA</last_name>
      <phone>404-851-8523</phone>
      <email>caitlin.guzowski@northside.com</email>
    </contact_backup>
    <investigator>
      <last_name>H. Kent Holland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asad Bashey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence E Morris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Solomon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melhem Solh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

